2020 Year in Review - Multiple Myeloma

Skip to main content

Multiple Myeloma

In Patients with RRMM, Circularly Permuted TRAIL, a Novel TRAIL Agonist, Is Combined with Thalidomide and Dexamethasone

Multiple Myeloma

GMMG-HD6 Study: Bortezomib, Lenalidomide, and Dexamethasone with or without Elotuzumab for Patients with Newly Diagnosed MM

Multiple Myeloma

Isatuximab for Patients with Previously Treated AL Amyloidosis: A Phase 2 Study

Multiple Myeloma

IKEMA Interim Analysis: Depth of Response and Response Kinetics of Isatuximab plus Carfilzomib and Dexamethasone in Patients with RMM

Multiple Myeloma

ICARIA-MM Study: Isatuximab plus Pomalidomide and Dexamethasone in Patients with RRMM with Gain(1q21)

Multiple Myeloma

GMMG-Concept Trial: Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Treatment of Patients with High-Risk MM

Multiple Myeloma

Multiple Myeloma Year in Review Introduction

Multiple Myeloma

Selinexor Combined with Pomalidomide and Dexamethasone for Treatment of Patients with RRMM

Multiple Myeloma, Venetoclax

In Patients with RRMM, Cobimetinib as a Single Agent and Combined with Venetoclax with or without Atezolizumab

Multiple Myeloma, Venetoclax

In Patients with RRMM, Treatment with Venetoclax plus Daratumumab and Dexamethasone ± Bortezomib

1
2
3
4

Page 2 of 4
Results 11 - 20 of 31